Developer docs
API playgroundTry for free, no card

Search company profiles

AccuGenomics

Full company profile

uuid000r95d

Namestring
AccuGenomics
Legal namestring
AccuGenomics, Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

AccuGenomics, Inc. is a privately held molecular diagnostics company founded in 2010 and headquartered in Wilmington, North Carolina. The company develops and commercializes SNAQ-SEQ, a proprietary multiplexed spike-in quality control technology for next-generation sequencing (NGS) assays. SNAQ-SEQ internal standards are added directly into each sample and co-vary through the entire workflow — chemistry, flow cell detection, and bioinformatics — providing per-sample measurement of technical and systemic errors, true Limit of Blank (LOB) and Limit of Detection (LOD) values, and elimination of false positives and false negatives at low variant allele frequencies. The underlying technology is exclusively licensed from the University of Toledo and protected by U.S. Patent No. 9,944,973.

The company sells a catalog of Accukit products targeting oncology (ctDNA MRD, CRC/NSCLC, Myeloid DNA, Onco1 LB, Mammo DNA), infectious disease (SARS-CoV-2), and biopharmaceutical manufacturing QC (Adventitious Agents AA20 for CHO cell bioproduction). AccuGenomics also offers a Custom Design Service producing client-specific SNAQ-SEQ standard mixes in as few as six weeks, and pursues companion diagnostics co-development partnerships with biopharma and diagnostic companies. Revenue derives from one-time catalog product sales, professional services for custom design work, and licensing royalties on the platform IP. The company operates with a 1-10 employee headcount out of a 5,000+ sq ft development and manufacturing facility, distributing through direct enterprise sales, regional distributors (SOMAGEN Diagnostics in Canada, MITEK Lab in Taiwan), and strategic channel partnerships including a 2024 alliance with LGC Clinical Diagnostics and a 2025 collaboration with 1Cell.Ai for liquid biopsy deployment in India and the U.S. The company is regulated-grade validated via FDA-led SEQC2 consortium participation and FNIH Biomarkers Consortium membership for MRD in AML.

Short descriptiontext

AccuGenomics is a Wilmington, NC-based molecular diagnostics company that develops and sells SNAQ-SEQ spike-in internal standards and Accukit product kits for NGS quality control, serving biopharmaceutical manufacturers, clinical diagnostics companies, and academic oncology research centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NGS quality control, spike-in standards, molecular diagnostics reagents, clinical sequencing assays, companion diagnostics development
Industry1 code
PRIMARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics Reagents
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Accukit Products
TypeOne Time License
Description

Sale of pre-configured spike-in QC standard kits including Accukit ctDNA MRD IS, Accukit Mammo DNA IS, Accukit CRC/NSCLC IS, Accukit Myeloid DNA, AccuKit Onco1 LB, AccuKit SARS-CoV-2, and Accukit Adventitious Agents (AA20). Products are sold for research use and targeted at biopharmaceutical manufacturers and clinical diagnostics companies.

accugenomics.com
2Custom Design Services
TypeProfessional Services
Description

Custom spike-in DNA or RNA standard mixes designed and developed for specific customer applications. Custom mixes can range from 6 to 66+ unique control regions.

accugenomics.com
3Licensing Royalties
TypeLicensing Royalties
Description

Technology licensed from University of Toledo for SNAQ-SEQ platform. Company holds exclusive license to patented technologies.

accugenomics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Standard catalog products with custom options available
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products sold as catalog items with part numbers. FOR RESEARCH USE ONLY. Contact sales for pricing. Custom design service available for specific requirements.

accugenomics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SNAQ-SEQ
Description

Spike-in quality control technology for next-generation sequencing applications that enables highly sensitive NGS and provides internal standards to improve assay accuracy and performance.

accugenomics.com
+2 more records
Core offering1 text field

AccuGenomics develops and sells SNAQ-SEQ multiplexed spike-in quality control standards that co-vary with patient samples through the entire next-generation sequencing workflow to provide direct measurement of technical and systemic errors per sample. Its Accukit product line of catalog internal standard kits addresses cancer diagnostics (ctDNA MRD, CRC/NSCLC, Myeloid DNA, Onco1 LB, Mammo DNA), infectious disease (SARS-CoV-2), and biomanufacturing QC (Adventitious Agents AA20), complemented by a Custom Design Service for bespoke spike-in mixes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 20-fold reduction in sequencing requirements while maintaining accuracy
+3 more records
Product overview1 text field

AccuGenomics is a commercial-stage molecular diagnostic company offering a portfolio of multiplexed spike-in quality control (QC) standards branded as SNAQ™-SEQ. The core product line includes: SNAQ™-SEQ Internal Standards (the foundational technology platform), specialized Accukit products for specific applications (ctDNA MRD IS, CRC/NSCLC IS, Myeloid DNA IS, Onco1 LB, SARS-CoV-2, Adventitious Agents AA20), and Custom Design Services. These products serve as run controls that co-vary with samples through NGS workflows to measure technical errors, establish limits of blank, and ensure assay sensitivity. The portfolio covers applications including cancer diagnostics (liquid biopsy, MRD, CNV detection), infectious disease testing (SARS-CoV-2, adventitious agents), and biopharmaceutical manufacturing QC.

Product and service9 records
1SNAQ-SEQ Internal Standards
2Accukit ctDNA MRD IS
3Accukit Mammo DNA IS
CategoryNGS Quality Control Reagents
Description

Internal standards designed for mammography-related DNA applications in cancer diagnostics, providing SNAQ-SEQ spike-in controls for breast cancer NGS assays.

4Accukit CRC/NSCLC IS
CategoryNGS Quality Control Reagents
Description

Internal standards collection for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) testing. Contains 13 clinically actionable targets including KRAS (G12D/C), EGFR (L858R, T790M), BRAF (V600E), AKT1 (E17K), ERBB2, KIT, NRAS, GNAS, BRCA2, and ESR1 variants. Compatible with amplicon and hybrid capture workflows including Illumina TST-170 and TSO500.

5Accukit Myeloid DNA IS
CategoryNGS Quality Control Reagents
Description

Internal standards for acute myeloid leukemia (AML) testing and measurable residual disease (MRD) detection. Provides variant-specific sensitivity controls for therapeutically relevant AML targets in each sample. Compatible with hybrid capture and amplicon-based library prep chemistries, available pre-fragmented for blood/plasma (cfDNA) or unfragmented for FFPE/tissues.

6AccuKit Onco1 LB
CategoryNGS Quality Control Reagents
Description

Blend of 13 synthetic DNA internal standards for clinically actionable oncogenic regions of the genome. Designed for ctDNA-based NGS hotspot assays, measuring variant allele frequencies. Provides sequence accuracy (limit of blank) and sensitivity control (limit of detection) for MRD applications. Fragmented to ~165bp average size for cell-free DNA assays.

7AccuKit SARS-CoV-2
CategoryNGS Quality Control Reagents
Description

First SARS-CoV-2 standard designed specifically for NGS applications. Contains 17 synthetic RNA overlapping constructs spanning the entire SARS-CoV-2 genome plus a complexity control (65k unique molecules). Co-locates with sample through RT step to control for systemic and technical errors, measure background error, and provide LOD control for qualitative detection assays.

8Accukit Adventitious Agents (AA20)
CategoryBiomanufacturing Quality Control Reagents
Description

NGS-library prep workflow for 20 common adventitious agents found in Chinese hamster ovary (CHO) cell bioproduction processes. Achieves sensitivity of 10 copies of target per ml of lysate. Includes targets such as Bovine adenovirus, Bovine coronavirus, Bovine parvovirus, Minute virus of Mice, Porcine Circovirus, and Seneca Valley Virus. Uses matched DNA and RNA SNAQ-SEQ spike-in standards.

9Custom Design Service
CategoryCustom Assay Development Services
Description

Custom SNAQ-SEQ internal standards development service. Provides custom spike-in DNA or RNA standard mixes in as little as 6 weeks. Supports custom internal standards mixes to enhance CNV detection, monitor viral pathogens, and improve variant allele frequency detection for ctDNA and FFPE tumor specimens. Custom mixes can range from 6 to 66+ unique control regions. Includes custom SNAQ-SEQ analysis tools development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-13
Description

Strategic collaboration to deliver ultra-sensitive liquid biopsy testing in India with plans to expand to the US. AccuGenomics will integrate its internal standards into 1Cell.Ai's liquid biopsy platform. The partnership aims to process tens of thousands of patient samples and improve cancer diagnostics accuracy across Asia and the US. Expected to enhance clinical reliability and support precision oncology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-13
Description

Integration of AccuGenomics' SNAQ-SEQ internal standards into 1Cell.Ai's liquid biopsy platform for improved testing accuracy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

Partnership to jointly develop quality control materials for next-generation sequencing tests. Collaboration will leverage LGC's expertise in quality control and AccuGenomics' NGS monitoring technologies. Goal is to develop accurate and reliable molecular diagnostics and quality control materials for cancer NGS testing as well as custom reference materials for NGS assay validation.

Strategic tierCoreTypeTechnology or Integration
Description

AccuGenomics holds exclusive license to suite of patented technologies from the University of Toledo that enable advanced genomic testing applications. SNAQ-SEQ technology originated from collaboration with University of Toledo and the Innovative Molecular Analysis Technologies Program of the NIH.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AccuGenomics joined the FNIH Biomarkers Consortium focused on Measurable Residual Disease in Acute Myeloid Leukemia (MRD in AML). Participation advances accuracy of targeted NGS testing of liquid biopsy samples. The FNIH Biomarkers Consortium is the preeminent public-private partnership focused on identifying, developing, and qualifying biomarkers that accelerate therapeutics and improve clinical care.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for AccuGenomics products in Canada.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for AccuGenomics products in Taiwan.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

LGC is a global life sciences measurement and diagnostics consumables leader whose portfolio includes NGS reference standards and QC materials — directly overlapping AccuGenomics' SNAQ-SEQ catalog. Note: LGC is also AccuGenomics' partner, making the relationship both collaborative and competitive.

TypeBroad incumbent
Description

Bio-Rad's Life Science segment supplies a broad catalog of molecular and NGS QC reagents, controls, and reference standards used in clinical genomics workflows — directly comparable to AccuGenomics' Accukit catalog across oncology, infectious disease, and biopharma QC.

TypeBroad incumbent
Description

Revvity's genomics/reagents business (built on the legacy Horizon Discovery reference standards franchise) is one of the closest direct competitors in synthetic NGS reference materials and controls for oncology and liquid biopsy assays.

TypeBroad incumbent
Description

ATCC produces authenticated biological reference materials, microbial and viral standards, and genomic reference DNA/RNA used as benchmarks in NGS assay validation — overlapping directly with AccuGenomics' reference-standard role across infectious disease and oncology.

TypeDirect peer
Description

Twist's synthetic biology platform supplies custom DNA controls, NGS target enrichment probes, and reference standards used in clinical and biopharma NGS workflows — closely comparable to AccuGenomics' custom SNAQ-SEQ design service.

6SeraCare (LGC subsidiary)
TypeDirect peer
Description

SeraCare (now part of LGC Clinical Diagnostics) is a longstanding supplier of ctDNA, oncology, and infectious-disease reference standards for NGS assay validation — overlapping with multiple Accukit product lines including ctDNA MRD IS, Myeloid DNA IS, and SARS-CoV-2 standards.

TypeBroad incumbent
Description

IDT supplies a broad NGS reagent portfolio including capture/library prep and quality controls used by diagnostic and biopharma labs, putting it adjacent to AccuGenomics' SNAQ-SEQ standards as a complement or substitute in commercial NGS workflows.

TypeBroad incumbent
Description

Promega manufactures nucleic acid purification, amplification, and quantification reagents including Maxwell and GoTaq lines used in clinical molecular labs — providing established alternatives to AccuGenomics on workflow control and detection chemistries.

TypeBroad incumbent
Description

Eurofins operates one of the largest global genomics service and reagent footprints including NGS reference materials and synthetic spike-in controls used by clinical and biopharma customers — comparable distribution scale and consumables catalog breadth.

TypeDirect peer
Description

1Cell.Ai is AccuGenomics' explicit commercial partner and an emerging player in liquid biopsy testing; the two firms share the same end-customers (clinical NGS users) and overlap directly in ctDNA/liquid biopsy assay workflows, with AccuGenomics' standards integrated into 1Cell.Ai's platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AccuGenomics

Molecular Diagnostics Reagentsaccugenomics.com

AccuGenomics is a Wilmington, NC-based molecular diagnostics company that develops and sells SNAQ-SEQ spike-in internal standards and Accukit product kits for NGS quality control, serving biopharmaceutical manufacturers, clinical diagnostics companies, and academic oncology research centers.

What AccuGenomics does

AccuGenomics, Inc. is a privately held molecular diagnostics company founded in 2010 and headquartered in Wilmington, North Carolina. The company develops and commercializes SNAQ-SEQ, a proprietary multiplexed spike-in quality control technology for next-generation sequencing (NGS) assays. SNAQ-SEQ internal standards are added directly into each sample and co-vary through the entire workflow — chemistry, flow cell detection, and bioinformatics — providing per-sample measurement of technical and systemic errors, true Limit of Blank (LOB) and Limit of Detection (LOD) values, and elimination of false positives and false negatives at low variant allele frequencies. The underlying technology is exclusively licensed from the University of Toledo and protected by U.S. Patent No. 9,944,973.

The company sells a catalog of Accukit products targeting oncology (ctDNA MRD, CRC/NSCLC, Myeloid DNA, Onco1 LB, Mammo DNA), infectious disease (SARS-CoV-2), and biopharmaceutical manufacturing QC (Adventitious Agents AA20 for CHO cell bioproduction). AccuGenomics also offers a Custom Design Service producing client-specific SNAQ-SEQ standard mixes in as few as six weeks, and pursues companion diagnostics co-development partnerships with biopharma and diagnostic companies. Revenue derives from one-time catalog product sales, professional services for custom design work, and licensing royalties on the platform IP. The company operates with a 1-10 employee headcount out of a 5,000+ sq ft development and manufacturing facility, distributing through direct enterprise sales, regional distributors (SOMAGEN Diagnostics in Canada, MITEK Lab in Taiwan), and strategic channel partnerships including a 2024 alliance with LGC Clinical Diagnostics and a 2025 collaboration with 1Cell.Ai for liquid biopsy deployment in India and the U.S. The company is regulated-grade validated via FDA-led SEQC2 consortium participation and FNIH Biomarkers Consortium membership for MRD in AML.

AccuGenomics firmographics

Firmographics
Name
AccuGenomics
Legal name
AccuGenomics, Inc.
Website
https://accugenomics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
AccuGenomics is a Wilmington, NC-based molecular diagnostics company that develops and sells SNAQ-SEQ spike-in internal standards and Accukit product kits for NGS quality control, serving biopharmaceutical manufacturers, clinical diagnostics companies, and academic oncology research centers.
Ownership category
akta.pro rank

AccuGenomics industry classification

Industry
Product category
Molecular Diagnostics Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • NGS quality control
  • Spike-in standards
  • Molecular diagnostics reagents
  • Clinical sequencing assays
  • Companion diagnostics development

Where AccuGenomics is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AccuGenomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Accukit Products: Sale of pre-configured spike-in QC standard kits including Accukit ctDNA MRD IS, Accukit Mammo DNA IS, Accukit CRC/NSCLC IS, Accukit Myeloid DNA, AccuKit Onco1 LB, AccuKit SARS-CoV-2, and Accukit Adventitious Agents (AA20). Products are sold for research use and targeted at biopharmaceutical manufacturers and clinical diagnostics companies.
  2. Custom Design Services: Custom spike-in DNA or RNA standard mixes designed and developed for specific customer applications. Custom mixes can range from 6 to 66+ unique control regions.
  3. Licensing Royalties: Technology licensed from University of Toledo for SNAQ-SEQ platform. Company holds exclusive license to patented technologies.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard catalog products with custom options available

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

AccuGenomics product offering

Product offering

Core offering

AccuGenomics develops and sells SNAQ-SEQ multiplexed spike-in quality control standards that co-vary with patient samples through the entire next-generation sequencing workflow to provide direct measurement of technical and systemic errors per sample. Its Accukit product line of catalog internal standard kits addresses cancer diagnostics (ctDNA MRD, CRC/NSCLC, Myeloid DNA, Onco1 LB, Mammo DNA), infectious disease (SARS-CoV-2), and biomanufacturing QC (Adventitious Agents AA20), complemented by a Custom Design Service for bespoke spike-in mixes.

Product overview

AccuGenomics is a commercial-stage molecular diagnostic company offering a portfolio of multiplexed spike-in quality control (QC) standards branded as SNAQ™-SEQ. The core product line includes: SNAQ™-SEQ Internal Standards (the foundational technology platform), specialized Accukit products for specific applications (ctDNA MRD IS, CRC/NSCLC IS, Myeloid DNA IS, Onco1 LB, SARS-CoV-2, Adventitious Agents AA20), and Custom Design Services. These products serve as run controls that co-vary with samples through NGS workflows to measure technical errors, establish limits of blank, and ensure assay sensitivity. The portfolio covers applications including cancer diagnostics (liquid biopsy, MRD, CNV detection), infectious disease testing (SARS-CoV-2, adventitious agents), and biopharmaceutical manufacturing QC.

Differentiator

Problem solved

Functional benefit

Brands

  • SNAQ-SEQ: Spike-in quality control technology for next-generation sequencing applications that enables highly sensitive NGS and provides internal standards to improve assay accuracy and performance.
  • Accukit
  • STARSEQ

Products and services

  • SNAQ-SEQ Internal Standards
  • Accukit ctDNA MRD IS
  • Accukit Mammo DNA IS Internal standards designed for mammography-related DNA applications in cancer diagnostics, providing SNAQ-SEQ spike-in controls for breast cancer NGS assays.
  • Accukit CRC/NSCLC IS Internal standards collection for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) testing. Contains 13 clinically actionable targets including KRAS (G12D/C), EGFR (L858R, T790M), BRAF (V600E), AKT1 (E17K), ERBB2, KIT, NRAS, GNAS, BRCA2, and ESR1 variants. Compatible with amplicon and hybrid capture workflows including Illumina TST-170 and TSO500.
  • Accukit Myeloid DNA IS Internal standards for acute myeloid leukemia (AML) testing and measurable residual disease (MRD) detection. Provides variant-specific sensitivity controls for therapeutically relevant AML targets in each sample. Compatible with hybrid capture and amplicon-based library prep chemistries, available pre-fragmented for blood/plasma (cfDNA) or unfragmented for FFPE/tissues.
  • AccuKit Onco1 LB Blend of 13 synthetic DNA internal standards for clinically actionable oncogenic regions of the genome. Designed for ctDNA-based NGS hotspot assays, measuring variant allele frequencies. Provides sequence accuracy (limit of blank) and sensitivity control (limit of detection) for MRD applications. Fragmented to ~165bp average size for cell-free DNA assays.
  • AccuKit SARS-CoV-2 First SARS-CoV-2 standard designed specifically for NGS applications. Contains 17 synthetic RNA overlapping constructs spanning the entire SARS-CoV-2 genome plus a complexity control (65k unique molecules). Co-locates with sample through RT step to control for systemic and technical errors, measure background error, and provide LOD control for qualitative detection assays.
  • Accukit Adventitious Agents (AA20) NGS-library prep workflow for 20 common adventitious agents found in Chinese hamster ovary (CHO) cell bioproduction processes. Achieves sensitivity of 10 copies of target per ml of lysate. Includes targets such as Bovine adenovirus, Bovine coronavirus, Bovine parvovirus, Minute virus of Mice, Porcine Circovirus, and Seneca Valley Virus. Uses matched DNA and RNA SNAQ-SEQ spike-in standards.
  • Custom Design Service Custom SNAQ-SEQ internal standards development service. Provides custom spike-in DNA or RNA standard mixes in as little as 6 weeks. Supports custom internal standards mixes to enhance CNV detection, monitor viral pathogens, and improve variant allele frequency detection for ctDNA and FFPE tumor specimens. Custom mixes can range from 6 to 66+ unique control regions. Includes custom SNAQ-SEQ analysis tools development.

Quantifiable outcome

  • 20-fold reduction in sequencing requirements while maintaining accuracy
  • +3 more outcomes

Companies that use AccuGenomics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

AccuGenomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AccuGenomics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • 1Cell.AicoreStrategic or Co-development Partner · 13 October 2025Strategic collaboration to deliver ultra-sensitive liquid biopsy testing in India with plans to expand to the US. AccuGenomics will integrate its internal standards into 1Cell.Ai's liquid biopsy platform. The partnership aims to process tens of thousands of patient samples and improve cancer diagnostics accuracy across Asia and the US. Expected to enhance clinical reliability and support precision oncology.
  • 1Cell.AicoreTechnology or Integration · 13 October 2025Integration of AccuGenomics' SNAQ-SEQ internal standards into 1Cell.Ai's liquid biopsy platform for improved testing accuracy.
  • LGC Clinical DiagnosticscoreStrategic or Co-development Partner · 8 October 2024Partnership to jointly develop quality control materials for next-generation sequencing tests. Collaboration will leverage LGC's expertise in quality control and AccuGenomics' NGS monitoring technologies. Goal is to develop accurate and reliable molecular diagnostics and quality control materials for cancer NGS testing as well as custom reference materials for NGS assay validation.
  • University of ToledocoreTechnology or IntegrationAccuGenomics holds exclusive license to suite of patented technologies from the University of Toledo that enable advanced genomic testing applications. SNAQ-SEQ technology originated from collaboration with University of Toledo and the Innovative Molecular Analysis Technologies Program of the NIH.
  • FNIH Biomarkers ConsortiumcoreStrategic or Co-development PartnerAccuGenomics joined the FNIH Biomarkers Consortium focused on Measurable Residual Disease in Acute Myeloid Leukemia (MRD in AML). Participation advances accuracy of targeted NGS testing of liquid biopsy samples. The FNIH Biomarkers Consortium is the preeminent public-private partnership focused on identifying, developing, and qualifying biomarkers that accelerate therapeutics and improve clinical care.
  • SOMAGEN DIAGNOSTICSminorChannel Partner/ Reseller/ DistributorAuthorized distributor for AccuGenomics products in Canada.
  • MITEK LAB CO LTDminorChannel Partner/ Reseller/ DistributorAuthorized distributor for AccuGenomics products in Taiwan.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

AccuGenomics competitors and assessment

Company assessment

Broad incumbents

  • LGC Clinical Diagnostics: LGC is a global life sciences measurement and diagnostics consumables leader whose portfolio includes NGS reference standards and QC materials — directly overlapping AccuGenomics' SNAQ-SEQ catalog. Note: LGC is also AccuGenomics' partner, making the relationship both collaborative and competitive.
  • Bio-Rad Laboratories: Bio-Rad's Life Science segment supplies a broad catalog of molecular and NGS QC reagents, controls, and reference standards used in clinical genomics workflows — directly comparable to AccuGenomics' Accukit catalog across oncology, infectious disease, and biopharma QC.
  • Revvity (formerly Horizon Discovery): Revvity's genomics/reagents business (built on the legacy Horizon Discovery reference standards franchise) is one of the closest direct competitors in synthetic NGS reference materials and controls for oncology and liquid biopsy assays.
  • ATCC: ATCC produces authenticated biological reference materials, microbial and viral standards, and genomic reference DNA/RNA used as benchmarks in NGS assay validation — overlapping directly with AccuGenomics' reference-standard role across infectious disease and oncology.
  • Integrated DNA Technologies (IDT / Danaher): IDT supplies a broad NGS reagent portfolio including capture/library prep and quality controls used by diagnostic and biopharma labs, putting it adjacent to AccuGenomics' SNAQ-SEQ standards as a complement or substitute in commercial NGS workflows.
  • Promega Corporation: Promega manufactures nucleic acid purification, amplification, and quantification reagents including Maxwell and GoTaq lines used in clinical molecular labs — providing established alternatives to AccuGenomics on workflow control and detection chemistries.
  • Eurofins Genomics: Eurofins operates one of the largest global genomics service and reagent footprints including NGS reference materials and synthetic spike-in controls used by clinical and biopharma customers — comparable distribution scale and consumables catalog breadth.

Direct peers

  • Twist Bioscience: Twist's synthetic biology platform supplies custom DNA controls, NGS target enrichment probes, and reference standards used in clinical and biopharma NGS workflows — closely comparable to AccuGenomics' custom SNAQ-SEQ design service.
  • SeraCare (LGC subsidiary): SeraCare (now part of LGC Clinical Diagnostics) is a longstanding supplier of ctDNA, oncology, and infectious-disease reference standards for NGS assay validation — overlapping with multiple Accukit product lines including ctDNA MRD IS, Myeloid DNA IS, and SARS-CoV-2 standards.
  • 1Cell.Ai: 1Cell.Ai is AccuGenomics' explicit commercial partner and an emerging player in liquid biopsy testing; the two firms share the same end-customers (clinical NGS users) and overlap directly in ctDNA/liquid biopsy assay workflows, with AccuGenomics' standards integrated into 1Cell.Ai's platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

AccuGenomics social profiles

Digital presence

AccuGenomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AccuGenomics leadership team

Management profile

Number of profiles

Profiles3 records

AccuGenomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AccuGenomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AccuGenomics

What does AccuGenomics do?

AccuGenomics develops and sells SNAQ-SEQ multiplexed spike-in quality control standards that co-vary with patient samples through the entire next-generation sequencing workflow to provide direct measurement of technical and systemic errors per sample. Its Accukit product line of catalog internal standard kits addresses cancer diagnostics (ctDNA MRD, CRC/NSCLC, Myeloid DNA, Onco1 LB, Mammo DNA), infectious disease (SARS-CoV-2), and biomanufacturing QC (Adventitious Agents AA20), complemented by a Custom Design Service for bespoke spike-in mixes.

Is AccuGenomics a public or private company?

AccuGenomics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AccuGenomics founded?

AccuGenomics was founded in 2010. It employs 1 to 10 people.

Where is AccuGenomics based?

AccuGenomics is headquartered in Wilmington, United States, in the North America region.

How does AccuGenomics make money?

Three revenue lines are on record. Accukit Products are the primary driver. The others are custom Design Services and licensing Royalties.

Who are AccuGenomics's main competitors?

Broad incumbents on record are LGC Clinical Diagnostics, Bio-Rad Laboratories, Revvity (formerly Horizon Discovery), ATCC, Integrated DNA Technologies (IDT / Danaher), Promega Corporation and Eurofins Genomics. Direct peers are Twist Bioscience, SeraCare (LGC subsidiary) and 1Cell.Ai.

Does AccuGenomics have an API?

No public API is recorded for AccuGenomics.

What industry is AccuGenomics in?

AccuGenomics's product category is Molecular Diagnostics Reagents. Its primary akta.pro industry code is HLAHAAAL, Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. ExpansionAccuGenomics, Inc. and 1Cell.Ai announced a strategic collaboration to deliver ultra-sensitive, clinically actionable liquid biopsy testing for cancer diagnostics across Asia, integrating AccuGenomics' Accukit™ CRC/NSCLC Internal Standards into 1Cell.Ai's OncoIndx NGS-based panel. The partnership expects to process tens of thousands of patient samples in the next year through 1Cell.Ai's clinical laboratory in India. 1Cell.Ai also plans to introduce the assay at its Foster City, California facility to support precision multi-omic testing for the U.S. market.BioSpaceFortis Life Sciences Partners With AccuGenomics to Expand Genomics PortfolioFortis Life Sciences became the exclusive channel partner for AccuGenomics in the United States, with co-exclusive rights in Europe. The partnership expands access to AccuGenomics' patented SNAQ-SEQ internal standards for next-generation sequencing, aiming to improve accuracy and sensitivity in precision medicine applications.WilmingtonbizWinners of inaugural NC BIONEER Venture Challenge announcedIsosceles Pharmaceuticals won first place in the inaugural NC BIONEER Venture Challenge, receiving a $20,000 investment and a one-year tenancy at UNCW's Center for Innovation and Entrepreneurship. The company develops synthetic CBD for pain relief as an opioid alternative. Other winners include AccuGenomics, Electronic Lab Logs, and IndiOmics.GlobeNewswirePrecision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL GrantPrecision Therapeutics' Helomics division was selected as the preferred laboratory for a NIIMBL grant to develop Accukit test kits for screening microbial and viral contamination in biopharmaceuticals. The NGS-based platform will detect 22 known contaminants at sensitivity levels required for Quality Control standards.PR NewswireAccuGenomics Provides an AccuKit to Qura Therapeutics as Part of a Research Collaboration AgreementAccuGenomics, Inc. announced it has provided its AccuKit-HIV to Qura Therapeutics and the HIV Cure Center at the University of North Carolina at Chapel Hill for evaluation in HIV research. The AccuKit is designed to characterize and quantify HIV reservoir and viral expression in CD4+ T cells before and after pharmacological intervention, utilizing AccuGenomics' Standardized Nucleic Acid Quantification technology. The HIV Cure Center is a joint initiative between UNC and GlaxoSmithKline, with Qura Therapeutics jointly owned by UNC-CH and GSK to manage the business side of the partnership.